Cologuard (Exact Sciences Corp.)December 5, 2017
Fecal-based colorectal cancer (CRC) screening tests have been used to detect hemoglobin, a measure of fecal occult blood (FOB), in stool, which is a nonspecific sign of CRC. In general, fecal-based CRC screening is a tool to improve CRC detection without the inconvenience (i.e., bowel preparation and time commitment) of screening colonoscopy or other invasive methods. Fecal-based assessment can also include the analysis of DNA found in the stool, detecting alterations that may occur during CRC carcinogenesis from cells that are shed into the stool. Stool-based tests using DNA biomarkers plus FOB screening are presumed to detect more CRCs than FOB alone. This report reviews the Cologuard (Exact Sciences Corp.) combination cancer screening test.
If you have a Hayes login, click here to view the full report on the Knowledge Center.